[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"growth-hormone-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:growth-hormone-deficiency":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,74,104,135,164,184,209,233,270,294,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100606244","evaluation-of-cardiometabolic-and-auxological-outcomes-of-ghd-patients-under-rhgh-or-lagh-with-stratification-according-to-igf-1-levels-100606244",false,"NCT07173036","Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels","Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under Recombinant Human or Long-acting Growth Hormone With Stratification According to IGF-1 Levels","METAB-BELGROW","Inclusion Criteria:\n\n* Diagnosed with growth hormone deficiency (GHD)\n* Treated with growth hormone (rhGH or LAGH)\n\nExclusion Criteria:\n\n* No exclusion criteria","ALL","5 Years","18 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","The METAB-BELGROW-LAGH study aims to prospectively evaluate the metabolic outcomes of Belgian children diagnosed with growth hormone deficiency (GHD) over a three-year period following the initiation of treatment with either daily recombinant human growth hormone (rhGH) or weekly long-acting growth hormone (LAGH). Patients will be stratified according to their IGF-1 levels. The primary objective is to assess the metabolic outcomes of children treated with daily rhGH over the first three years. The secondary objectives include comparing the metabolic outcomes between patients treated with daily rhGH and those treated with weekly LAGH, and characterizing metabolic profiles based on IGF-1 levels. To achieve these objectives, both standard-of-care (SOC) and additional data will be collected at scheduled follow-up visits (baseline, 6, 12, 24, and 36 months), including clinical, auxological, and biological parameters. Additional metabolic markers, inflammatory and endothelial biomarkers will be assessed. In a subset of patients, carotid intima-media thickness (cIMT) and body fat distribution (via DEXA-scan) will also be measured.",[28],"Growth Hormone Deficiency",[30,31,32,33],"metabolic outcomes","auxological outcomes","recombinant human growth hormone","long acting growth hormone","NOT_YET_RECRUITING","2026-05-08",{"date":37,"type":38},"2026-05-11","ACTUAL",{"date":40,"type":22},"2026-07-01",{"date":42,"type":22},"2031-09-01",{"name":44,"class":45},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":18,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100502316","a-us-non-interventional-effectiveness-and-safety-study-of-patients-treated-with-skytrofa-100502316","NCT05820672","A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA","A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)","SkybriGHt","Inclusion Criteria:\n\n* Patients who are on treatment with SKYTROFA (lonapegsomatropin)\n* Patients being clinically managed in USA\n* Patients with an appropriate written informed consent\u002Fassent as applicable for the age of the patient\n\nExclusion Criteria:\n\n* Patients participating in any interventional clinical study",{"count":55,"type":22},900,"OBSERVATIONAL","The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care",[28],[60,61],"Human Growth Hormone","SKYTROFA","RECRUITING","2026-04-20",{"date":65,"type":38},"2026-04-21",{"date":67,"type":38},"2023-03-20",{"date":69,"type":22},"2033-03",{"name":71,"class":72},"Ascendis Pharma Endocrinology Division A\u002FS","INDUSTRY",27,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100491605","phase-4-effects-of-gh-and-lirglutide-on-agrp-100491605","NCT05681299","Effects of GH and Lirglutide on AgRP","Effects of Administration of Growth Hormone, Without and With Liraglutide, on AgRP, Energy and Glucose Metabolism in Healthy and GH Deficient Humans","Inclusion Criteria:\n\nHEALTHY SUBJECTS\n\n1. 40 healthy subjects, 20 male, 20 female, ages 18-45 yr.: (i) 20 (10 male, 10 female) who are overweight\u002FClass 1 Obese (BMI 25-34.9) with abdominal fat accumulation (central adiposity) defined by waist circumference (WC) ≥ 102 cm in men, ≥ 88 cm in women, except in East\u002FSouth Asians for whom the criteria will be WC ≥ 90 men and ≥ 80 women; (ii) 20 (10 male,10 female) who are lean (BMI 19-24.9) and not meeting these WC criteria.\n2. No medical conditions except being overweight\u002Fobese in half of subjects\n3. No prescription medication or other drug use\n4. On screening testing: BP\\\u003C140\u002F\\\u003C90 mmHg, HbA1c\\\u003C5.7%, FPG\\\u003C100 mg\u002FdL, normal IGF-1 and TSH levels.\n5. Premenopausal women: use of nonhormonal method of contraception\n6. Current non-smoker\n\nGH DEFICIENT SUBJECTS\n\n1. 24 patients with isolated GH deficiency:12 males, 12 females.\n2. Ages 18-45 years\n3. Diagnosis of isolated GH deficiency based on accepted, BMI-appropriate GH stimulation test cut offs within 12 months of enrollment\n4. No prior GH therapy within 12 months of study enrollment\n5. Normal thyroid, adrenal and gonadal function documented by accepted stimulation test and clinical criteria\n6. Premenopausal women: use of nonhormonal method of contraception\n\nExclusion Criteria:\n\nHEALTHY SUBJECTS\n\n1. History of malignancy, diabetes, thyroid cancer or pancreatitis\n2. Recent dieting, weight change \\>5%, pregnancy or lactation or heavy exercise\n3. Use of glucocorticoids, hormonal supplements or medications that could affect GH or IGF-1 or for weight loss within 6 months of enrollment\n\nGH DEFICIENT SUBJECTS\n\n1. DM requiring medication\n2. HbA1C \\> 7.5\n3. Malignancy, pancreatitis or thyroid cancer history.\n4. Deficiency of other pituitary hormones, liver or renal disease\n5. Use of glucocorticoids, hormonal supplements or medications that could affect GH or IGF-1 or for weight loss within 6 months of enrollment\n\n5\\. Recent dieting, weight change \\> 5%, pregnancy, lactation or heavy exercise 6. Current smoking",true,"45 Years",{"count":84,"type":22},40,[86],"PHASE4","This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of the study will consist of a 7-day baseline period including 2 days of testing and 21 days on therapy with visits on days 2, 7, 14 and 21. Testing before, during and at the completion of each arm will include blood sampling and assessments of insulin resistance, energy expenditure and body composition.",[89,28],"Healthy",[91,92,93],"growth hormone","liraglutide","AgRP","2026-03-02",{"date":96,"type":38},"2026-03-04",{"date":98,"type":38},"2023-05-01",{"date":100,"type":22},"2028-04-30",{"name":102,"class":45},"Columbia University",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":19,"enrollmentInfo":113,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":133,"leadSponsor":134,"locationsCount":73},"100498843","a-post-authorisation-safety-study-pass-of-patients-treated-with-lonapegsomatropin-100498843","NCT05775523","A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin","A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin","SkyPASS","Inclusion Criteria:\n\n* Paediatric patients with GHD who are on treatment with lonapegsomatropin\n* Patients being clinically managed in Europe or the USA\n* Appropriate written informed consent\u002Fassent as applicable for the age of the patient\n* Patients willing to comply with follow-up requirements of the study\n\nExclusion Criteria:\n\n* Patients participating in any interventional clinical trial for short stature\n* Patients being treated with a GH or IGF-1 therapy, other than lonapegsomatropin, at enrollment\n* Patients for whom treatment with lonapegsomatropin is contraindicated\n* Patients with closed epiphyses\n* Patients with active malignant tumours\n* Patients under antitumour therapy within the past 12 months prior to instituting GH therapy\n* Hypersensitivity to somatropin or any of the excipients in lonapegsomatropin","1 Year",{"count":114,"type":22},500,"The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.",[28],[60,118,119,120,121,122,123,124,125,126,28,127,128,110],"hGH","rhGH","GHD","Long Acting Growth Hormone","Lonapegsomatropin","Prodrug","Growth Failure","Growth Hormone Replacement Therapy","Sustained Release Growth Hormone","TransCon hGH","Skytrofa","2026-02-02",{"date":131,"type":38},"2026-02-04",{"date":67,"type":38},{"date":69,"type":22},{"name":71,"class":72},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":81,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100074759","chromosome-18-clinical-research-center-100074759","NCT00227253","Chromosome 18 Clinical Research Center","The Chromosome 18 Clinical Research Center","Chromosome18","Inclusion Criteria:\n\n* Must have a confirmed diagnosis of Chromosome 18 or be the parent\u002Fguardian of a child with Chromosome 18\n* Subject must be at least one year of age to participate in the clinical examination aspect of the study (due to issues of venous access and blood volume required to complete studies)\n* General health status: good\n\nExclusion Criteria:\n\n* Pregnant women\n* Dead fetuses\n* Prisoners\n* Non-viable neonates or neonates of uncertain viability",{"count":144,"type":22},4000,"Our vision, that of the researchers at the University of Texas Health Science Center at San Antonio, is that every person with a chromosome 18 abnormality will have an autonomous and healthy life. Our mission is to provide families affected by chromosome 18 abnormalities with comprehensive medical and educational information. Our goals are to provide definitive medical and education resources for the families of individuals with chromosome 18 abnormalities; perform and facilitate groundbreaking clinical and basic research relating to the syndromes of chromosome 18; and to provide treatments to help these individuals overcome the effects of their chromosome abnormality.",[147,28,148],"Chromosome Aberrations","Hypomyelination",[150,151,152,153],"Phenotype","Growth","Genotype","Chromosome 18","2026-01-02",{"date":156,"type":38},"2026-01-06",{"date":158,"type":4},"1993-09",{"date":160,"type":22},"2040-12",{"name":162,"class":45},"The University of Texas Health Science Center at San Antonio",2,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100488830","the-agrp-and-ghigf-1-axis-in-children-100488830","NCT05645211","The AgRP and GH\u002FIGF-1 Axis in Children","Agouti-related Peptide (AgRP) and the GH\u002FIGF-1 Axis in Children","Healthy children\n\nInclusion Criteria:\n\n1. Ambulatory male and female children aged 5-17 years\n2. Normal weight at birth\n3. Height between the 3rd and 99th percentiles of the mean as per the CDC growth percentiles.\n\nExclusion Criteria:\n\n1. Genetic defects, chronic illnesses.\n2. Current prescription medication use\n3. Use of glucocorticoids, thyroid hormone or medications that may affect the GH-IGF-1 axis within 6 months of study entry.\n\nChildren with GH deficiency:\n\nInclusion Criteria:\n\n1. Ambulatory male and female children aged 5-9 years who are prepubertal\n2. Normal weight at birth\n3. Growth failure\n4. Peak GH response to 2 GH stimulation tests \\\u003C 10 ng\u002Fml\n5. Normal renal and liver function\n\nExclusion criteria:\n\n1. Multiple pituitary hormone deficiencies,\n2. GH deficiency or poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.\n3. History of diabetes or malignancy\n4. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.\n\nChildren with idiopathic Short Stature:\n\nInclusion Criteria:\n\n1. Ambulatory male and female children aged 5-9 years who are prepubertal\n2. Normal weight at birth\n3. Height \\>2.25 SD below mean for age\n4. Peak GH response to 2 stimulation tests \\>10 ng\u002Fml or normal IGF-1 and IGFBP-3 levels\n5. No prior supplemental growth hormone exposure\n6. Normal renal and liver function\n\nExclusion criteria:\n\n1. Poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.\n2. History of diabetes or malignancy\n3. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.","17 Years",{"count":173,"type":22},156,"Recent data support the existence of a GH-Agouti-related peptide (AgRP) axis. The neuropeptide AgRP promotes food intake and has important effects on energy homeostasis. Recent evidence suggest that GH stimulates AgRP and AgRP may mediate some of GH's important nutritional and metabolic effects. main goals of this project are to characterize, for the first time, plasma levels of AgRP in children and to determine how these relate to GH and IGF-1 levels, age, body composition, clinical and other endocrine parameters. To accomplish this, we will conduct two studies, one being a cross-sectional study that will measure AgRP levels in 140 healthy children ages 5-17 and the second being a prospective study that will measure the change in plasma AgRP levels in response to GH treatment in 16 children who receive this as part of their clinical care for GH deficiency or short stature.",[28],"2025-08-25",{"date":178,"type":38},"2025-08-26",{"date":180,"type":22},"2026-06-10",{"date":182,"type":22},"2027-12-31",{"name":102,"class":45},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":103},"100569458","belux-children-outcome-during-adulthood-with-ghd-100569458","NCT06694506","BELux Children OutcoME During A(@)Dulthood With GHD","BELux Children OutcoME During A(@)Dulthood With Growth Hormone Deficiency","BELCOME@GHD","Inclusion Criteria:\n\n* Age \\> or = 18 years\n* Diagnosed with child-hood onset growth hormone deficiency (CO-GHD) (no exclusion criteria: isolated or multiple GHD, idiopathic or organic, severe or partial)\n* Registered in the BELGROW registry (informed consent at the time of inclusion in registry)\n* Stopped treatment with rhGH for growth after 2011\n* Persistent GHD at the end of growth\n\nExclusion Criteria:\n\n* No exclusion criteria",{"count":193,"type":22},200,[25],"Our objective is to evaluate the outcome in adulthood of Belgian and Luxembourgish patients treated with rhGH during childhood for CO-GHD. The primary goal is to determine the proportion of adult CO-GHD patients who continue to receive regular medical follow-up and those still undergoing rhGH therapy using a questionnaire. Secondary objectives include assessing the regularity of follow-up and compliance with treatment in adulthood, evaluating possible comorbidities, health issues, lifestyle, living environment, and quality of life. Additionally, we aim to assess the metabolic profile in adulthood, particularly focusing on BMI, glycemic, and lipid data, for patients who consent to share their current clinical and biological data. Data will be described according to treatment adherence and CO-GHD etiology\u002Fphenotypes (e.g., idiopathic vs. organic GHD, isolated vs. combined GHD, partial vs. severe GHD).",[28,197],"Adult Growth Hormone Deficiency",[199,200],"Growth Hormone","Adult","2024-11-15",{"date":203,"type":38},"2024-11-19",{"date":205,"type":22},"2024-12-15",{"date":207,"type":22},"2029-08-01",{"name":44,"class":45},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":216,"maxAge":19,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":103},"100557799","evaluation-of-the-propensity-of-patients-under-rhgh-to-envision-a-modification-of-their-treatment-regimen-toward-lagh-100557799","NCT06542809","Evaluation of the Propensity of Patients Under rhGH to Envision a Modification of Their Treatment Regimen Toward LAGH","TOWARD-LAGH","Inclusion Criteria:\n\n* Belgian and Luxembourgish patients currently under rhGh treatment in its various official indications (as per the Belgian RIZIV\u002FINAMI monitor : growth hormone deficiency, Turner Syndrome, chronic renal insufficiency, Prader-Willi syndrome, Small for gestational age, Noonan Syndrome, SHOX gene deficiency) and included in the BELGROW Registry\n* Male -female\n* 0-18 years\n* Free written or e-consent and oral consent\n\nExclusion Criteria:\n\n* No exclusion criteria","1 Day",{"count":114,"type":22},[25],"Daily subcutaneous injections of rhGH can be burdensome for patients, leading to poor adherence and reduced growth outcomes. This has spurred the development of long-acting GH (LAGH) analogues that allow for weekly, biweekly, or monthly injections. Previous studies on LAGH analogues have demonstrated their non-inferiority compared to daily rhGH in terms of increasing growth velocity and improving body composition in children and adults with growth hormone deficiency (GHD), respectively, without significant and unexpected adverse events. Since 2020, three molecules have received approval from the Food and Drug Administration (FDA) for the treatment of pediatric GHD: lonapegsomatropin, somatrogon, and somapacitan. These LAGH analogues may offer better patient acceptance, improved tolerance, and greater therapeutic flexibility. However, these LAGH analogues could also be associated with potential clinical issues in terms of therapeutic monitoring, incidence and duration of side effects, and long-term safety due to a non-physiological GH profile. The introduction of these new LAGH products will require clinicians to identify optimal candidates for LAGH therapy and gain knowledge on monitoring and adjusting treatment.",[28],[199,222,223,224],"New treatment","Propensity","Pediatric","2024-08-02",{"date":227,"type":38},"2024-08-07",{"date":229,"type":38},"2024-04-15",{"date":231,"type":22},"2026-03-01",{"name":44,"class":45},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":81,"sex":17,"minAge":241,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":256,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":269},"100381852","growing-up-with-the-young-endocrine-support-system-yess-100381852","NCT04252001","Growing up With the Young Endocrine Support System (YESS!)","Growing up With the Young Endocrine Support System (YESS!): Innovative E-technology to Improve Transition From Paediatric to Adult Care","YESS","Inclusion Criteria:\n\n* Aged 15 to 20 years old.\n* Diagnosed with congenital adrenal hyperplasia, hypogonadotropic hypogonadism, Turner syndrome, Klinefelter syndrome, growth hormone deficiency, combined pituitary hormone deficiency, Androgen insensitivity syndrome, thyroid dysgenesis or Addison's disease\n\nExclusion Criteria:\n\n* Lack of a mobile phone or tablet.\n* Intellectual disability or language barrier leading to inability to use the YESS! game or the control game.","15 Years","20 Years",{"count":244,"type":22},160,[25],"Transition from paediatric to adult endocrinology is a challenge for adolescents, families and doctors. Up to 25% of young adults with chronic endocrine disorders are lost to follow-up ('drop-out') once the young adult moves out of paediatric care. Non-attendance and sub-optimal medical self-management can lead to serious and expensive medical complications. In a pilot study, adolescents suggested the use of e-technology to become more involved in the transition process. The investigators have designed and developed the YESS! game, a tool to help improve medical self-management in adolescents with chronic endocrine disorders. The hypothesis is that adolescents playing the YESS! game will show a larger increase in self-management score during the first year of transition and will have a lower drop-out rate at the adult endocrine outpatient clinic (OPC), compared to adolescents who do not play the game.",[248,249,28,250,251,252,253,254,255],"Congenital Adrenal Hyperplasia","Hypogonadotropic Hypogonadism","Combined Pituitary Hormone Deficiency","Turner Syndrome","Klinefelter Syndrome","Addison's Disease","Androgen Insensitivity Syndrome","Thyroid Dysgenesis",[257,258,259],"Serious game","Endocrinology","Transition","2023-09-06",{"date":262,"type":38},"2023-09-07",{"date":264,"type":22},"2024-12-01",{"date":266,"type":22},"2026-12-01",{"name":268,"class":45},"dr. Laura C. G. de Graaff-Herder",7,{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":277,"maxAge":4,"enrollmentInfo":278,"targetDuration":280,"studyType":56,"phases":4,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":103},"100423808","long-term-safety-and-effectiveness-of-growtropin-ii-treatment-in-children-with-short-stature-100423808","NCT04798690","Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature","Open, Multi-center, Non-interventional, Prospective\u002F Retrospective Observational Study on Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature","Inclusion Criteria:\n\n* Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)\n* Children who has official height record at least 6 months prior\n\nExclusion Criteria:\n\n* Children with Epiphyseal closure","2 Years",{"count":279,"type":22},2500,"10 Years","This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.",[28,283,251,284],"Idiopathic Short Stature","Small for Gestational Age","2023-04-11",{"date":287,"type":38},"2023-04-12",{"date":289,"type":38},"2021-02-08",{"date":291,"type":22},"2031-12",{"name":293,"class":72},"Dong-A ST Co., Ltd.",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":301,"minAge":19,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":307,"conditions":308,"keywords":314,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":103},"100371853","phase-2-growth-hormone-replacement-therapy-for-retried-professional-football-players-100371853","NCT04121780","Growth Hormone Replacement Therapy for Retried Professional Football Players","Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency","Inclusion Criteria:\n\n* The subject is willing to provide a signed and dated informed consent indicating that he understands the purpose and procedures required for the study and is willing to participate in the study.\n* Former NFL player\n* At least one year since retirement from football\n* Less than 76 years of age\n* Diagnosis of GHD on clinical grounds by a neurologist and an endocrinologist GHD\n\nExclusion Criteria:\n\n* History of pre-existing brain disease other than concussion or TBI\n* History of a premorbid disabling condition that interferes with outcome assessments\n* Contraindication to GH therapy\n* Type I and II Diabetes mellitus\n* Active malignant disease\n* Acute critical illness, heart failure, or acute respiratory failure\n* Subjects who are deficient in cortisol, testosterone or thyroid at screening will be excluded until hormone abnormalities have been corrected.","MALE","76 Years",{"count":304,"type":22},42,[306],"PHASE2","This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).",[309,310,311,312,313,28],"TBI (Traumatic Brain Injury)","Concussion, Brain","Sport Injury","Anterior Pituitary Hyposecretion Syndrome","Hypopituitarism",[315,120,199,316,317],"TBI","Norditropin Flexpro","cognition disorders","2023-02-06",{"date":320,"type":38},"2023-02-08",{"date":322,"type":38},"2019-10-08",{"date":324,"type":22},"2026-09",{"name":326,"class":45},"Center for Neurological Studies",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":277,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":103},"100178992","long-term-safety-and-effectiveness-of-growth-hormone-with-ghd-ts-crf-sga--iss-and-pws-in-children-100178992","NCT01604395","Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children","An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. \u002F Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA, ISS and PWS in Children","LGS","Inclusion Criteria:\n\n* short stature children aged 2 years or more\n* children with GHD,TS, CRF, SGA or ISS\n* written informed consent from the person, person's parent or legal guardian",{"count":336,"type":22},6000,"The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj.\u002FEutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).",[28,251,339,284,283],"Chronic Renal Failure",[120,341,342,343,344,345],"TS","CRF","SGA","ISS","PWS","2021-02-17",{"date":348,"type":38},"2021-02-21",{"date":350,"type":4},"2012-01",{"date":352,"type":22},"2032-12-31",{"name":354,"class":72},"LG Chem"]